80
Participants
Start Date
March 10, 2021
Primary Completion Date
June 7, 2022
Study Completion Date
November 22, 2022
Inhaled Aviptadil
Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
Placebo
Aviptadil Placebo will be used for this arm.
Başkent University School of Medicine, Ankara
Hacettepe University School of Medicine, Ankara
Dicle Üniversitesi Tıp Fakültesi Hastanesi, Diyarbakır
Başakşehir Çam ve Sakura Şehir Hastanesi, Istanbul
Health Sciences University Yedikule Training and Research Hospital, Istanbul
Prof. Dr. Feriha Öz Acil Durum Hastanesi, Istanbul
Prof. Dr. Murat Dilmener Acil Durum Hastanesi, Istanbul
Kocaeli Üniversitesi Tıp Fakültesi Hastanesi, Kocaeli
Karadeniz Teknik Üniversitesi Tıp Fakültesi Hastanesi, Trabzon
Lead Sponsor
Centurion Pharma
INDUSTRY